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Zaheer-Ud-Din Babar1*, Andy Gray2, Ayyaz Kiani3, Sabine Vogler4, Peri Ballantyne5 and Shane Scahill6Scientific journals are most often used to disseminate
the end products of research, but also have an important
role as instruments of change. One year after the launch
of the Journal of Pharmaceutical Policy and Practice, the
focus of articles published has been on pharmaceutical
health systems research, including contemporary issues
related to medicines management, socio-behavioral as-
pects of pharmacy and macro pharmaceutical issues.
Our most cited articles ranged from those on generic
medicines in Jordan [1], antibiotics sensitivity, usage and
access in India and Namibia [2,3], to a review of national
medicines policies around the globe [4]. At this point the
Journal has successfully provided a forum to publish
within its specified themes. However, given the techno-
logical and social changes in health, medicines and public
policy, we are keen to promote the Journal of Pharma-
ceutical Policy and Practice as a platform for change, in
order to advance specific agendas. We would argue that
this change agenda is underpinned by the following issues:Global demographic change: growing health
disparities
Global demographic change encompasses far more than
declining fertility and an aging population. Social and hu-
man capital are far more mobile than they once were. Im-
migration has resulted in multicultural populations in most
developed countries [5]. For example, in United States
alone, 321 different languages are spoken. By 2050, what
are currently regarded as racial and ethnic minorities will
constitute 50% of the total population of the US [6]. Health
disparities among these populations are of particular
concern [7]. What is of most interest to readers of this
journal is how these demographic changes will impact
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required.Changes in healthcare and community pharmacy
practice
Worldwide, a community pharmacy is generally the most
common point at which the public accesses medicines, as
well as health advice. However, in many countries, commu-
nity pharmacy is seen as having interests that are oppos-
itional to public health and motivated purely by profit. As
a result, community pharmacy as a sector is often margina-
lised from the health and social care system. It is seen as a
rather insular profession, busy with its own concerns, and
not engaged with debates and decisions in the wider world
of health policy [8]. Medicines use issues at the points of
transition between ambulatory and institutional healthcare
are also fertile areas for investigation and innovation.
It has been argued that pharmacy practice research
has a lower profile than research undertaken by other
healthcare professionals [9]. This is especially surprising
at a time when some governments are advocating greater
integration of pharmacy into mainstream healthcare and
also facing increasing demands for access to expensive
medicines [10]. Although pharmacy practice research has
recently attracted large grants, and some robust evidence
is emerging, there remains a paucity of knowledge on the
quality of services delivered by pharmacists and a lack of
evidence in terms of patient outcomes and value for
money. Indeed, what evidence does exist is dominated by
data from developed country settings [11].
Successful implementation of pharmacy practice research
cannot be achieved simply by information dissemination,
training, regulation and compliance with guidelines. Just
because a programme or service has been shown to dem-
onstrate positive outcomes for patients does not mean that
it will be easily implemented in practice [12,13]. For ex-
ample, a recent study [14] of the community pharmacy
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interaction was dependent on patients’ understanding of
the pharmacists’ role, the perceived hierarchy and position
held by general practitioners, and experience of what actu-
ally occurs during the MUR interaction [14]. We need to
challenge our practices and beliefs if things are to change
and the future research agenda on pharmacy service models
has to focus on these issues [15]. In addition, pharmacy
practice research has to be seen as linked to overall pharma-
ceutical policy, including pharmaceutical pricing and reim-
bursement strategies and demand-side measures to, for
instance, enhance generic uptake and/or a more rational use
of medicines.
Technology is rapidly changing
There is an increasing use of technology in the delivery
and management of healthcare. There is use of automa-
tion and robotics at hospital and community pharmacies,
electronic prescribing, e- communication, use of robotics,
pharmacists’ access to integrated patient records- all are
changing at a very fast pace and are directly related to
how patients and consumers are accessing and using med-
icines [8]. Social media is on the rise and there is no rea-
son to suggest that this will be any less the case for those
engaged with the pharmacy sector
What could be on the new research horizon?
In the context of the trends outlined here, what will the
healthcare sector look like in 20–30 years? What might
medicines use and access look like? It is likely there will be
many changes and the way we think, act and formulate re-
search questions will be different. Might many of the current
questions we are asking be irrelevant? Might new profes-
sional alliances be formed that transform the effectiveness of
how the public is using medicines? To enable such a shift,
there will be a need for a significant rethink of the models of
care through which medicines are delivered. New ap-
proaches to delivering patient services will emerge [8].
Researchers can no longer expect to secure funding
for projects solely focused on pharmacy practice [16]. In
order to maximize the impact of their work pharmacy
practice researchers will need to include physicians and
nurses at the very least and preferably other health pro-
fessionals [16]. Moreover, pharmacy practice research
teams have to involve researchers with different aca-
demic backgrounds such as sociologists, economists,
and epidemiologists in-order to have their research
more widely recognized and accepted. The healthcare
system of the future demands a connected, transdisciplinary
and collaborative approach, and the same applies to
pharmaceutical policy and practice research. The Jour-
nal of Pharmaceutical Policy and Practice stands ready
to not only publish that research, but to promote that
agenda, and to ask those tough and relevant questions.Author details
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